Regulation of Mitochondrial Metabolism by Tyr-phosphorylated ATP Synthase Alpha-Subunit and its Therapeutic Implications in Prostate Cancer
Regulation of Mitochondrial Metabolism by Tyr-phosphorylated ATP Synthase Alpha-Subunit and its Therapeutic Implications in Prostate Cancer
批准号:
10657090
负责人:
Nupam P Mahajan
金额:
$47.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-01 至 2028-03-31
关键词:
ACK1 GeneATP Synthesis PathwayATP phosphohydrolaseAcuteBindingCategoriesCause of DeathDataDependenceDisease remissionEnzyme StabilityExclusionIn SituMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of prostateMetabolicMitochondriaMolecularNucleotidesOncogenicOxidative PhosphorylationPathway interactionsPhosphorylationPhosphotransferasesPhysiologicalProcessProliferatingPropertyProstateProtein Tyrosine KinaseProteinsRegulationResistanceResistance developmentRoleSignal TransductionStructureSurfaceTherapeuticTyrosine Kinase Inhibitorabirateroneaddictionantagonistcancer cellcancer therapycastration resistant prostate cancerenzalutamideflexibilityin vivoinhibitormenmetabolic phenotypemitochondrial metabolismmouse modelpatient derived xenograft modelpreventprostate cancer modelprostate cancer progressionresponsetumortumor growth
中文摘要
项目摘要
英文摘要
Project Abstract
Cancer cell mitochondria switch their metabolic phenotypes to meet the challenges of high-energy demand and
macromolecular synthesis. Acute dependence of tumors on oncogenic tyrosine kinase signaling support their
rapid proliferation, however, direct relevance of the kinase activity for mitochondria to support these high-energy
processes remains obscure. Serendipitously, we uncovered that a non-receptor tyrosine kinase, ACK1,
phosphorylates ATP synthase F1 α-subunit (ATP5F1a) at Tyr243 and Tyr246 (Tyr200 & 203 in mature protein,
respectively) that increased ATP synthase activity specifically in the cancer cells. Mechanistically, ATP5F1a-
phosphorylation not only excluded its binding to its physiological inhibitor, ATPase Inhibitory Factor 1 (IF1), but
also created a supporting structure that extended from the bound non-catalytic nucleotide to the surface,
reducing the flexibility and thereby increasing the stability of the enzyme. A new class of ACK1 inhibitor, (R)-9b
reversed this process, inducing mitophagy and mitigating tumor growth. Consistently, a marked increase in
ATP5F1a-phosphorylations was observed as normal prostate progressed to the malignant stage. Overall, these
data provide the molecular evidence for cancer cell `mitochondrial addiction’ to Tyr-kinase indulgence, and
reveals (R)-9b as a ‘mitocan’ that compromises the unique metabolic needs of cancer cells.
Castration resistant prostate cancer (CRPC) remains an incurable malignancy with limited treatment options and
is a significant cause of deaths in men worldwide (15). Limited efficacy and rapid development of resistance for
Enzalutamide and Abiraterone, AR antagonist treatment have established a new paradigm-to achieve realistic
remission, other cancer specific pathways, including metabolic must be compromised. This proposal is directed
towards detailed characterization of mitochondrial metabolism modulatory properties of ACK1/ATP5F1a
signaling and examine ability of (R)-9b to overcome Enzalutamide and abiraterone-resistant CRPCs. The
specific aims are as follows:
Specific Aim 1. Examine the mechanism by which ATP5F1a-phosphorylation regulates its activity in prostate
cancer
Specific Aim 2. Explore the role of ACK1/ATP5F1a signaling in prostate cancer models
Specific Aim 3. Detail in vivo characterization of ACK1/ATP5F1a signaling in enzalutamide and abiraterone-
resistance in mouse models of prostate cancer and patient derived xenografts (PDXs)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting a Novel Signaling Nexus pACK/pCSK/pLCK in Immune Checkpoint Blockade (ICB)-Resistant Prostate Cancer
-
批准号:10734202
-
项目类别:
-
资助金额:$48.44万
-
财政年份:2023
-
负责人:Nupam P Mahajan
-
依托单位:
Targeting a Novel Epigenetic Signaling Nexus ACK1-pY88H4-AR/AR-V7 in Drug Resistant Metastatic Prostate Cancer
-
批准号:9977692
-
项目类别:
-
资助金额:$33.83万
-
财政年份:2017
-
负责人:Nupam P Mahajan
-
依托单位:
Targeting a Novel Epigenetic Signaling Nexus ACK1-pY88H4-AR/AR-V7 in Drug Resistant Metastatic Prostate Cancer
-
批准号:9308352
-
项目类别:
-
资助金额:$36.98万
-
财政年份:2017
-
负责人:Nupam P Mahajan
-
依托单位:
Targeting a Novel Epigenetic Signaling Nexus ACK1-pY88H4-AR/AR-V7 in Drug Resistant Metastatic Prostate Cancer
-
批准号:10112834
-
项目类别:
-
资助金额:$33.87万
-
财政年份:2017
-
负责人:Nupam P Mahajan
-
依托单位:
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer
-
批准号:8082792
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2010
-
负责人:Nupam P Mahajan
-
依托单位:
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer
-
批准号:8460126
-
项目类别:
-
资助金额:$30.48万
-
财政年份:2010
-
负责人:Nupam P Mahajan
-
依托单位:
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer
-
批准号:8246962
-
项目类别:
-
资助金额:$32.85万
-
财政年份:2010
-
负责人:Nupam P Mahajan
-
依托单位:
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer
-
批准号:7985538
-
项目类别:
-
资助金额:$35.26万
-
财政年份:2010
-
负责人:Nupam P Mahajan
-
依托单位:
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer
-
批准号:8657844
-
项目类别:
-
资助金额:$31.41万
-
财政年份:2010
-
负责人:Nupam P Mahajan
-
依托单位: